Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors

Breast Cancer Research and Treatment

Volumn 55, Issue 2, 1999, Pages 169-177

  Ménard, Sylvie ^a   Casalini, Patrizia ^a   Tomasic, Gorana ^a   Pilotti, Silvana ^a   Cascinelli, Natale ^a   Bufalino, Rosaria ^a   Perrone, Franco ^b   Longhi, Chiara ^a   Rilke, Franco ^a   Colnaghi, M Ines ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biologic variables; Classification; Pathologic variables; Prognosis

Indexed keywords

PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MITOSIS; ONCOGENE NEU; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; TISSUE NECROSIS;

EID: 0032796773     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006262324959     Document Type: Article

References (25)

1. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992
2. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30: 117-126, 1994
3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843-2877, 1996
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
5. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970, 1993
6. Keshgegian AA: Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma: immunocytochemical hormone receptors and prognostic factors. Arch Pathol Lab Med 118: 240-244, 1994
7. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A: Prognostic significance of HER2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44-49, 1991
8. Visscher DW, Castellani R, Wykes SM, Sarkar FH, Hussain ME: Concurrent abnormal expression ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma. Breast Cancer Res Treat 28: 261-266, 1993
9. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994
10. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S: Relationship between p53 expression and other prognostic factors in human breast carcinoma: an immunohistochemical study. Am J Clin Pathol 100: 213-217, 1993
11. Hilsenbeck SG, Clark GM, Chamness GC, Osborne CK: Untangling the multiple prognostic factor problem. Proc Am Assoc Cancer Res 34: 193, 1993
12. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, Robertson JFR, Ellis IO: Pathological prognostic factors in breast cancer: IV. Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 27: 219-226, 1995
13. Martignone S, Pellegrini R, Villa E, Tandon NN, Mastroianni A, Tagliabue E, Ménard S, Colnaghi MI: Characterization of two monoclonal antibodies directed against the 67kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin Exp Metastasis 10: 379-386, 1992
14. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992
15. Benzecri JP: Analyse des Donnes. II. Analyse des Correspondance. Dunod, Paris, 1973
16. Greenacre M, Hastie T: The geometric interpretation of the correspondence analysis. JASA 82: 437-447, 1987
17. Peto R, Pike MC, Breslow NE, Cox RD, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observations of each patient. Br J Cancer 35: 1-27, 1977
18. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41: 177-185, 1996
19. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Ménard S: Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 14: 85-94, 1996
20. Melief CJM, Kast WM: Potential immunogenicity of oncogene and tumor suppressor gene products. Curr Opin Immunol 5: 709-713, 1993
21. Pupa SM, Ménard S, Andreola S, Colnaghi MI: Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53: 5864-5866, 1993
22. Evans AJ, Pinder SE, Ellis IO, Sibbering DM, Elston CW, Poller DN, Wilson ARM: Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and c-erbB-2 oncogene expression. Clin Radiol 49: 559-562, 1994
23. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708, 1996
24. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adélaïde J, Birnbaum D: Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 14: 2773-2778, 1994
25. Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isley M, Rudenstam C-M, Collins J, Castiglione M, Senn H-J, Goldhirsch A: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 10: 696-705, 1992